Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections
Phase 3
- Conditions
- Disseminated intravascular coagulation (DIC)
- Registration Number
- JPRN-jRCT2080220059
- Lead Sponsor
- ASAHIKASEI PHARMA CORPORATIO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-Patients given a diagnosis of DIC
-Patients with malignant hematopoietic tumors or infections as the underlying diseases which directly caused DIC
-Inpatients
-Without distinction of sex, etc.
Exclusion criteria:
-Children under 15, etc.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy, Safety
- Secondary Outcome Measures
Name Time Method